Advertisement

ICON Public Limited Company ICLR

Set alert

Price alert · ICLR

All alert types
203.22 USD -8.14 -3.85%

As of Nov 2, 3:35 PM ET

Bid
203.11 × 1
Ask
203.80 × 4
203.17 Day range 211.00
66.57 52-week range 219.04
YTD
+11.52%
1 year
+18.27%
Open
206.00
Prev close
211.36
Mkt cap
15.24B
Vol
500.54K
Avg vol
917.70K
EPS
2.50
P/E
81.38
Div yield
0.00%
More statistics
Low
203.17
High
211.00
Forward P/E
18.24
Beta
1.24
Short ratio
3.06
Inst. own
110.99%
Dividend
0.00
Ex-div date
Earnings
Feb 24, 2027
50-d avg
171.23
200-d avg
145.67
1y target
225.12

1Y chart

Chart tools
Interval

Events in this range
  • May 27, 2026Earnings: 2.52; estimate 3.13; surprise -19.49%
  • Jun 23, 2026Earnings: 2.5; estimate 2.46; surprise 1.63%
  • Jul 29, 2026Earnings: 2.56; estimate 2.55; surprise 0.39%
  • Oct 27, 2026Earnings: 2.66; estimate 2.62; surprise 1.53%
  • Oct 29, 2026Rating: Truist Securities · Buy → Buy
  • Oct 29, 2026Rating: Barclays · Equal-Weight → Equal-Weight
  • Oct 29, 2026Rating: UBS · Neutral → Neutral
  • Oct 29, 2026Rating: TD Cowen · Buy → Buy
  • Oct 29, 2026Rating: Citigroup · Neutral → Neutral
  • Oct 29, 2026Rating: RBC Capital · Outperform → Outperform
Signals (54)
NameDateAgo
RSI: OverboughtOct 28, 20265 days ago
MACD: Buy SignalOct 15, 20262 weeks ago
SMA: BullishOct 14, 20262 weeks ago
SMA: BearishOct 6, 20263 weeks ago
SMA: BullishOct 5, 20264 weeks ago
SMA: BearishOct 1, 20261 month ago
MACD: Sell SignalOct 1, 20261 month ago
SMA: BullishSep 24, 20261 month ago
MACD: Buy SignalSep 24, 20261 month ago
MACD: Sell SignalSep 23, 20261 month ago
SMA: BearishSep 22, 20261 month ago
SMA: BullishSep 21, 20261 month ago
SMA: BearishSep 18, 20261 month ago
MACD: Buy SignalSep 14, 20261 month ago
SMA: BullishSep 11, 20261 month ago
SMA: BearishAug 31, 20262 months ago
MACD: Sell SignalAug 27, 20262 months ago
MACD: Buy SignalAug 19, 20262 months ago
MACD: Sell SignalJul 9, 20263 months ago
RSI: OverboughtJun 26, 20264 months ago
MACD: Buy SignalJun 25, 20264 months ago
SMA: BullishJun 24, 20264 months ago
MACD: Sell SignalJun 16, 20264 months ago
SMA: BearishJun 10, 20264 months ago
SMA: BullishJun 8, 20264 months ago
SMA: BearishJun 5, 20265 months ago
SMA: BullishJun 4, 20265 months ago
RSI: OverboughtJun 3, 20265 months ago
RSI: OverboughtJun 1, 20265 months ago
MACD: Buy SignalMay 28, 20265 months ago
RSI: OverboughtMay 28, 20265 months ago
MACD: Sell SignalMay 15, 20265 months ago
MACD: Buy SignalApr 30, 20266 months ago
SMA: BullishApr 29, 20266 months ago
SMA: BearishApr 24, 20266 months ago
MACD: Sell SignalApr 24, 20266 months ago
SMA: BullishApr 14, 20266 months ago
MACD: Buy SignalFeb 27, 20268 months ago
RSI: OversoldFeb 10, 20268 months ago
RSI: OversoldFeb 5, 20269 months ago
SMA: BearishFeb 4, 20269 months ago
SMA: BearishJan 30, 20269 months ago
SMA: BullishJan 21, 20269 months ago
SMA: BearishJan 20, 20269 months ago
MACD: Sell SignalJan 12, 20269 months ago
RSI: OverboughtJan 6, 202610 months ago
MACD: Buy SignalJan 2, 202610 months ago
SMA: BullishDec 22, 202510 months ago
SMA: BearishDec 19, 202510 months ago
MACD: Sell SignalDec 17, 202510 months ago
SMA: BullishNov 25, 202511 months ago
SMA: BullishNov 21, 202511 months ago
MACD: Buy SignalNov 21, 202511 months ago
SMA: BearishNov 4, 202512 months ago

Key statistics

Market cap
15.83B
Enterprise value
18.84B
Trailing P/E
84.54
Forward P/E
18.24
PEG ratio
0.65
Price / sales
1.92
Price / book
1.73
EPS (TTM)
2.50
Beta
1.24
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
5.26%
Revenue (TTM)
8.23B
Revenue growth
-2.90%
Free cash flow
538.14M
Total cash
808.98M
Total debt
3.51B
Return on equity
4.70%
Shares outstanding
74.92M
Short % of float
4.50%
50-day average
171.23
200-day average
145.67

Analyst view

Consensus: buy

Buy
Price target (mean) 225.12 +10.8% upside
Target (low)
155.00
Target (mean)
225.12
Target (high)
268.00
Ratings (0m) 18 10 buy · 7 hold · 1 sell
  • Strong buy1
  • Buy9
  • Hold7
  • Sell0
  • Strong sell1

Next earnings

Feb 24, 2027

Expected Feb 24, 2027. Consensus EPS estimate 2.82.

Earnings history

Financials — quick view

All financials
ICLR Revenue — quarterly 2.02B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
ICLR Net income — quarterly 122.13M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
ICLR EPS — quarterly 1.59
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

ICLR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 20262.83———
Oct 27, 2026Sep 30, 20262.622.66+0.04+1.53%
Jul 29, 2026Jun 30, 20262.552.56+0.01+0.39%
Jun 23, 2026Mar 31, 20262.462.50+0.04+1.63%
May 27, 2026Dec 31, 20253.132.52-0.61-19.49%
Oct 22, 2025Sep 30, 20253.283.31+0.03+0.91%

Upgrades / downgrades

ICLR analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026RBC CapitalmainOutperformOutperform
Oct 29, 2026CitigroupmainNeutralNeutral
Oct 29, 2026TD CowenmainBuyBuy
Oct 29, 2026UBSmainNeutralNeutral
Oct 29, 2026BarclaysmainEqual-WeightEqual-Weight
Oct 29, 2026Truist SecuritiesmainBuyBuy

About ICON Public Limited Company

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers testing services comprising bioanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, medical imaging, real world intelligence, site and patient, and strategic solutions. Additionally, it provides therapeutics for cardiovascular, central nervous system, endocrine and metabolic disorders, hepatology, infectious diseases, internal medicine immunology, and oncology. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Sector
Healthcare
Industry
Diagnostics & Research
Country
Ireland
Website
iconplc.com

News

Your note

Sign in to keep a note on ICLR — it syncs with the Stock Master app.

Insider holders

ICLR insider holders
InsiderRelationLatest transactionDateShares held
BALFE BARRY EDWARDChief Executive OfficerSaleAug 9, 20264,804
CLERKIN NIGELChief Financial OfficerSaleAug 10, 20265,881
CLIMAX JOHN PH.D.DirectorSaleAug 10, 20262,087
GRAIS LINDA SUE M.D.DirectorSaleAug 10, 20266,162
LYONS EMEROfficerSaleOct 22, 2026990
MCCAGUE EUGENE PACELLIDirectorSaleAug 10, 20263,811

Institution ownership

ICLR institution ownership
Holder% heldSharesValueReported
Artisan Partners Limited Partnership11.31%8,636,4061.83BJun 29, 2026
Wellington Management Group, LLP6.97%5,320,0541.12BJun 29, 2026
FMR, LLC6.90%5,271,3211.11BJun 29, 2026
Invesco Ltd.6.89%5,264,2361.11BJun 29, 2026
Harris Associates L.P.5.85%4,468,146944.39MJun 29, 2026
Brave Warrior Advisors, LLC4.13%3,153,308666.48MJun 29, 2026

Fund ownership

ICLR fund ownership
Holder% heldSharesValueReported
Artisan Partners Funds Inc.-Artisan International Value Fund8.83%6,744,9021.43BJun 29, 2026
HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Select Fund3.10%2,369,000500.71MJun 29, 2026
AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund1.37%1,042,659220.38MJul 30, 2026
Fidelity Puritan Trust-Fidelity Low-Priced Stock Fund1.27%973,587205.78MJul 30, 2026
VANGUARD WINDSOR FUNDS-Vanguard Windsor Fund1.24%943,171199.35MJul 30, 2026
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund1.22%933,744197.36MJul 30, 2026
Advertisement